Icotinib: efficacy in different solid tumors and gene mutations

• Published in: Anti-cancer drugs Vol. 31; no. 3; pp. 205 - 210
• Main Authors: Zhao, Qian, Cheng, Jie, Chen, Pingping, Sun, Jiewei, Guan, Shengjiang
• Format: Journal Article
• Language: English
• Published: England Wolters Kluwer Health, Inc. All rights reserved 01-03-2020; Copyright Wolters Kluwer Health, Inc. All rights reserved
• Subjects: Carcinoma, Non-Small-Cell Lung - drug therapy; Crown Ethers - therapeutic use; ErbB Receptors - antagonists & inhibitors; ErbB Receptors - genetics; Humans; Lung Neoplasms - drug therapy; Mutation; Neoplasms - drug therapy; Neoplasms - genetics; Quinazolines - therapeutic use
• ISSN: 0959-4973; 1473-5741
• DOI: 10.1097/CAD.0000000000000861

Icotinib is a first-generation inhibitor of epidermal growth factor receptor, which has been approved by the Chinese National Medical Products Administration, for the treatment of non-small cell lung cancer with epidermal growth factor receptor sensitive mutations. In addition, icotinib also shows moderate activity in other solid tumors driven by epidermal growth factor receptor, including non-small cell lung cancer with epidermal growth factor receptor rare non-resistant mutations, and esophageal cancer with epidermal growth factor receptor amplification or overexpression. This article reviews the efficacy of icotinib in different solid tumors with different epidermal growth factor receptor alterations.